Abstract：Objective To evaluate immunogenicity of one dose or two dose salk strain inactivated poliovirus vaccine(Salk-IPV) among children under seven years. Methods Searching "National Center for Biotechnology Information, NCBI", "Cochrane Library" "China Biology Medicine disc, CBMd", "China National Knowledge Infrastructure, CNKI", "Wanfang Database, WF", studies for assessing immunogenicity of Salk-IPV were included. The seroconversion rate (SR) of neutralization antibody (NA) of specific type of polio virus with an interval of one month after vaccination was used as our endpoints. Pooled SR with 95% Confidence Interval (CI) was calculated by RevMan5.1 software. The association between seroconversion and age at administration was described by R 3.2.2 program. Results A total of 11 studies were included. One dose of Salk-IPV seroconvert 29% (95%CI:19%-39%),41%(95%CI:31%-51%) and 38% (95%CI:28%-48%) of infants aged 7 years against serotypes I, Ⅱ, and Ⅲ on average, while 2 doses seroconvert 82% (95%CI:74%-90%),83% (95%CI:77%-88%) and 91% (95%CI:87%-95%), respectively. Seroconversion increased with the starting age for both one dose and two dose schedules.Conclusion Routine immunization with at least 2 doses of Salk-IPV was recommended as a sequential schedule with two-valent oral polio virus vaccine and Salk-IPV was applied.
李倩, 胡昱, 张兵, 陈雅萍. 7岁以下儿童接种1剂次或2剂次Salk-IPV免疫效果的Meta分析[J]. 预防医学, 2016, 28(9): 874-878,895.
LI Qian, HU Yu, ZHANG Bing, CHEN Ya-ping. A meta-analysis on immunogenicity of one dose or two dose salk strain inactivated poliovirus vaccine among children under seven years. Preventive Medicine, 2016, 28(9): 874-878,895.
[1]World Health Organization. Conclusions and recommendations of the ad hoc advisory committee on poliomyelitis eradication, Geneva, 21–22 September 2004[J]. Weekly Epidemiologicel Record, 2004, 79(45): 401-408. [2]PLOTKIN S A. Inactivated polio vaccine for the United States: a missed vaccination opportunity[J]. Pediatric Infectious Disease Journal, 1995, 14(10):835-839. [3]RESIK S, TEJEDA A, LAGO P M, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba[J]. Journal of Infectious Diseases, 2010, 201(9): 1344-1352. [4]MOHAMMED A J,ALAWAIDY S,BAWIKAR S, et al. Fractional doses of inactivated poliovirus vaccine in Oman[J]. New England Journal of Medicine, 2010, 362(25):2351-2359. [5]JAIN P K, DUTTA A K, NANGIA S, et al. Seroconversion following killed polio vaccine in neonates[J]. Indian Journal of Pediatrics, 1997, 64(4):511-515. [6]LINDER N, YARON M, HANDSHER R, et al. Early immunization with inactivated poliovirus vaccine in premature infants[J]. Journal of Pediatrics, 1995, 127(1):128-130. [7]RESIK S,TEJEDA A,SUTTER R W, et al. Priming after a fractional dose of inactivated poliovirus vaccine[J]. New England Journal of Medicine, 2013, 368(5):416-424. [8]SIMASATHIEN S, MIGASENA S, BEUVERY C, et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants[J]. Scandinavian Journal of Infectious Diseases, 1994, 26(6):731-738. [9]MCBEAN A M, THOMS M L, ALBRECHT P , et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines[J]. American Journal of Epidemiology, 1988, 128(3):615-628. [10]SINGH J, RAVI R N, DUTTA A K, et al. Immunogenicity of enhanced potency inactivated polio vaccine[J]. Indian Pediatrics, 1992, 29(11):1353-1356. [11]WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand[J]. Journal of Infectious Diseases,1997(Suppl.1):S215-227. [12]GALINDO M, LAGO P M, CCERES V, et al. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba[J]. New England Journal of Medicine, 2007, 356(15):1536-1544. [13]SIMOES E A F, JOHN T J. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency[J]. American Journal of Diseases of Children, 1985, 139(10):977-980. [14]World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2012-conclusions and recommendations[J]. Weekly Epidemiological Record,2013,88(1):1-16. [15]李杰,庄辉.脊髓灰质炎病毒疫苗株感染与免疫策略[J].中华流行病学杂志, 2002 , 23(4):314 -316. [16]Global Polio Eradication Initiative. The Polio eradication and endgame strategic plan 2013—2018[EB/OL]. [20015-12-10]. http://www.who.int/immunization/sage/meetings/2012/november/1_DRAFTGPEI_EndgameStrategicPlan23Oct12.pdf. [17]CDC. Outbreak of poliomyelitis -Dominican Republic and Haiti,2000—2001[J].MMWR, 2001, 50(39):855 -856. [18]ANON. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus——Philippines, 2001[J]. MMWR,2001, 50(40):874-875. [19]ROUSSET D,RAKOTO-ANDRIANARIVELO M,RAZAFIN-DRATSIMANDRESY R, et al. Recombinant vaccine-derived poliovirus in Madagascar[J]. Emerging Infectious Diseases,2003,9(7):885-887. [20]CDC.Circulation of type 2 vaccine-derived poliovirus in Egypt, 1982—1993[J].MMWR,2001,50(3):41 -42. [21]HOME C. Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2007-June 2008[J]. MMWR, 2008, 57(35):967-970. [22]MILLER M A, SUTTER R W, STREBEL P M, et al. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule [J]. JAMA, 1996, 276(12):967-971.
